TY - JOUR
T1 - Renal transplantation in the first year of life
T2 - The treatment of choice for infants with end-stage renal disease
AU - Najarian, John S.
AU - Almond, P. Stephen
AU - Mauer, Michael
AU - Chavers, Blanche
AU - Nevins, Thomas
AU - Kashtan, Clifford
AU - Matas, Arthur J.
PY - 1992/6
Y1 - 1992/6
N2 - The treatment of choice for end-stage renal failure within the first year of life is controversial. Between September 1970 and February 1991, we performed 28 kidney transplants (27 primary, 1 retransplant, 23 living donor, 5 cadaver) in infants less than 1 yr of age (mean, 7 ± 2 months; range, 6 wk to 12 months). The 1-yr patient survival rate for living donor recipi-ents was 100% versus 20% for cadaver recipients (P = 0.0001). The 1-yr graft survival rate for living donor recipients was 96% versus 20% for cadaver recipients (P= 0.001). The 1-yr patient survival rate for cyclosporin A (CSA) recipients (N = 12) was 100% versus 75% for non-CSA recipients (P = 0.03). The 1-yr graft survival rate for CSA recipients was 92% versus 75% for non-CSA recipients (P = 0.08). There was no difference in the number of rejection episodes or serum creatinine levels in CSA versus non-CSA recipients. Compared with pretransplant values, the mean post-transplant standard deviation scores (SDS) for height (N = 18), weight (N = 22), and head circumference (N = 8) improved: height SDS from -1.9 to -1.5 (not significant); weight SDS from -2.5 to 0.6 (P < 0.0005); head circumference SDS from -2.0 to -0.7 (P = 0.01). Because no other renal replacement therapy can match these results, we conclude that renal transplantation is the treatment of choice for infants with end-stage renal failure.
AB - The treatment of choice for end-stage renal failure within the first year of life is controversial. Between September 1970 and February 1991, we performed 28 kidney transplants (27 primary, 1 retransplant, 23 living donor, 5 cadaver) in infants less than 1 yr of age (mean, 7 ± 2 months; range, 6 wk to 12 months). The 1-yr patient survival rate for living donor recipi-ents was 100% versus 20% for cadaver recipients (P = 0.0001). The 1-yr graft survival rate for living donor recipients was 96% versus 20% for cadaver recipients (P= 0.001). The 1-yr patient survival rate for cyclosporin A (CSA) recipients (N = 12) was 100% versus 75% for non-CSA recipients (P = 0.03). The 1-yr graft survival rate for CSA recipients was 92% versus 75% for non-CSA recipients (P = 0.08). There was no difference in the number of rejection episodes or serum creatinine levels in CSA versus non-CSA recipients. Compared with pretransplant values, the mean post-transplant standard deviation scores (SDS) for height (N = 18), weight (N = 22), and head circumference (N = 8) improved: height SDS from -1.9 to -1.5 (not significant); weight SDS from -2.5 to 0.6 (P < 0.0005); head circumference SDS from -2.0 to -0.7 (P = 0.01). Because no other renal replacement therapy can match these results, we conclude that renal transplantation is the treatment of choice for infants with end-stage renal failure.
KW - Infant
KW - Kidney failure
KW - Kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=0026878283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026878283&partnerID=8YFLogxK
M3 - Article
C2 - 1498279
AN - SCOPUS:0026878283
SN - 1046-6673
VL - 2
SP - S228-S233
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 12 SUPPL.
ER -